BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Mesalamine
1
Reevaluating aminosalicylates role in maintaining remission in ulcerative colitis: Systematic review and meta-analysis in the era of biologics
12/18/2025 5:53:46 AM | Browse: 74 | Download: 306
2
Shared decision-making improves adherence to mesalamine in ulcerative colitis: A prospective, multicenter, non-interventional cohort study in Germany
6/12/2025 3:45:51 AM | Browse: 232 | Download: 832
3
Ulcerative colitis and bullous pemphigoid - a direct association or a medication side effect: A case report
12/12/2024 7:29:57 AM | Browse: 188 | Download: 800
4
Delayed-release oral mesalamine tablet mimicking a small jejunal gastrointestinal stromal tumor: A case report
6/24/2022 9:00:25 AM | Browse: 679 | Download: 1447
5
Diagnosis of acute intermittent porphyria in a renal transplant patient: A case report
1/12/2022 7:13:00 AM | Browse: 642 | Download: 1501
6
Nonasthmatic eosinophilic bronchitis in an ulcerative colitis patient – a putative adverse reaction to mesalazine: A case report and review of literature
9/22/2020 3:17:14 AM | Browse: 940 | Download: 2109
7
Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review
3/7/2019 3:51:24 AM | Browse: 1454 | Download: 2289
8
Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial
5/4/2017 8:16:34 AM | Browse: 1796 | Download: 3288
9
Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?
11/12/2015 7:10:00 PM | Browse: 1694 | Download: 2713
10
Isolated fever induced by mesalamine treatment
9/16/2014 4:56:00 PM | Browse: 1585 | Download: 1956
11
Noninfectious interstitial lung disease during infliximab therapy: Case report and literature review
9/15/2014 8:53:00 PM | Browse: 1257 | Download: 1479
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.